Finerenone-Empagliflozin Combination Therapy in Apparent Resistant Hypertension: A CONFIDENCE Trial Post Hoc Analysis. (PubMed, JACC Adv) - Oct 25, 2026 - P2 | "aTRH affected approximately 40% of participants and marked a higher-risk phenotype responsive to finerenone-empagliflozin, with BP reductions comparable to spironolactone but without the excess hyperkalemia that limits its use in CKD."
Journal • Retrospective data • Atherosclerosis • Cardiovascular • Chronic Kidney Disease • Diabetes • Hypertension • Metabolic Disorders • Nephrology • Obesity • Renal Disease • Type 2 Diabetes Mellitus
|
|
Amy K Mottl; Charlie Scott; Hiddo J L Heerspink; Janet B McGill; Javier Morales; Jennifer B Green; Johannes F E Mann; Julio Rosenstock; Li Li; Masaomi Nangaku; Matthew R Weir; Meike Brinker; Michelle M Estrella; Muthiah Vaduganathan; Peter Rossing; Rajiv Agarwal; Ricardo Correa-Rotter; Sankar D Navaneethan; Yehuda Handelsman
|